BOEHRINGER-INGELHEIM
2.6.2022 15:12:08 CEST | Business Wire | Press release
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. Boehringer Ingelheim aims to use these antibodies to direct therapeutic effector mechanisms such as antibody-drug conjugates (ADCs) and T-cell engagers exclusively to tumor cells, and to that end develop a range of highly targeted cancer treatments.
“Boehringer Ingelheim believes that these promising antibodies in-licensed from A*STAR will help us advance potent therapeutic candidates against key molecular cancer targets,” says Clive R. Wood, Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim and continues: “We look forward to developing these assets for a broad range of cancers with the goal to deliver breakthrough opportunities for patients.”
Boehringer Ingelheim is pioneering a range of versatile therapeutic platforms in order to develop innovative medicines that target the tumor directly (tumor cell-directed therapies) or that enable the immune system to target the tumor (immune cell-targeted therapies). One tumor cell-directed modality is antibody drug conjugates, which allows for delivery of toxins directly into tumor cells. Another is T-cell engagers facilitating direct contact between T-cells and tumor cells, leading to T-cell-mediated killing of the tumor. Both technologies are directed towards markers on the surface of cancer cells, also known as antigens, in order to attack tumor cells but spare healthy tissues.
The innovative antibodies from A*STAR can potentially enable the development of safer, more efficacious therapies as they selectively bind to antigens that are highly expressed on tumor cells but are absent on normal healthy tissues.
Under the terms of the agreement, Boehringer Ingelheim will be responsible for further research, preclinical and clinical development as well as commercialization of targeted cancer therapies using the antibodies from A*STAR. A*STAR may receive payments totalling >100 million EUR in upfront and success-based development and commercialization milestones.
The technology used to identify the unique A*STAR antibodies resulted from a multi-institutional collaboration in Singapore. A*STAR’s Genome Institute of Singapore (GIS) and Institute of Bioengineering & Bioimaging (IBB) generated antibodies which exclusively target antigens that were initially identified from gastric cancer cells. Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by A*STAR, then optimized the antibodies and confirmed their applicability to a range of other solid cancers. EDDC also demonstrated the utility of these antibodies in directing different therapeutic modalities selectively to cancer cells.
Professor Damian O'Connell, Chief Executive Officer of EDDC, says, “As Singapore's national drug discovery and development platform, EDDC is proud to translate great science in Singapore into valuable assets that can enable the precise treatment of cancer. We believe that Boehringer Ingelheim, with its broad expertise and technologies, is the right partner to maximize the potential of these antibodies for the development of safer, more targeted therapies for cancer patients.”
Professor Tan Sze Wee, Assistant Chief Executive (Enterprise) of A*STAR, says, “These antibodies were developed in Singapore through close collaboration across multiple institutions. There was also strong support by the Singapore Gastric Cancer Consortium. The agreement is testament to the best-in-class research taking place in Singapore. Cancer is a devastating disease, and we hope the fruits of our research can improve patient outcomes.”
Please click on the link for “Note to Editors’ and ‘References’:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005475/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Expands into Global Direct-to-Device Services through Strategic Collaboration with Elveo Mobile17.8.2026 09:30:00 CEST | Press release
SES, a global leader in space solutions, today announced an expanded strategic investment and collaboration with Elveo Mobile (Elveo), the new company created through the completion of the Lynk and Omnispace merger. Elveo unites the heritage of two pioneers in direct-to-device (D2D) services and will deliver mobile connectivity from space to mobile phones, devices and machines around the world. SES will support Elveo in accelerating its delivery of powerful, cost-effective global D2D services. SES and Elveo will also work together on global spectrum initiatives that will enable Elveo to unlock delivery of D2D solutions. By partnering with Elveo, SES deepens its commitment with access to its expansive, global space and ground infrastructure, while also supporting Elveo's go-to-market, engineering, operations and regulatory needs. The collaboration will enable SES to enhance current services for its mobile telecom, enterprise, and government customers around the world. SES users will ben
Trading Central Launches a UCITS ETF17.8.2026 09:30:00 CEST | Press release
Trading Central SA (“Trading Central”) announces the launch of a UCITS European Quant ETF in partnership with HANetf Asset Management, one of Europe’s leading white-label UCITS ETF and ETC platforms. The following ETF is now trading on Euronext Paris (eligible to PEA), Milan, Dublin, and Börse Frankfurt, and is coming soon to more European stock exchanges and in currencies besides the Euro. Trading Central Quant Europe 50 Equity UCITS ETF (TCQE) J.P. Morgan serves as fund administrator and custodian, while GTX acts as the market maker across these exchanges. This release marks Trading Central’s continued expansion into investable products, supporting self-directed retail clients with its award-winning, proprietary financial research and data. “For years, Trading Central has helped investors make more informed decisions through independent research and analytics,” said Alain Pellier, CEO of Trading Central SA. “The introduction of our TC Quant ETF is a natural next step in our mission—o
The Estée Lauder Companies and University of Leeds Partner to Advance the Future of Complexion Shade Matching14.8.2026 15:00:00 CEST | Press release
New research aims to tackle one of beauty’s most persistent challenges: accurately matching shade complexion-enhancing products to the full, diverse spectrum of global skin tones The Estée Lauder Companies Inc. (NYSE: EL) today announced a research collaboration with the School of Design, University of Leeds, United Kingdom, and Dr. Kaida Xiao, a world-renowned leader in color science and visual perception. Despite significant advances in beauty innovation, finding the right foundation or concealer shade remains one of the most common consumer frustrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260814256032/en/ Foundation shades are evaluated as part of color science research. By combining advanced color science with research into how consumers perceive their own skin, this partnership aims to strengthen the development of luxury and prestige complexion-enhancing products with more precise shade matching and improve
ZPG Reaches Agreement to Sell Hometrack to Providence Equity Partners14.8.2026 11:00:00 CEST | Press release
ZPG today announced an agreement with Providence Equity Partners for the sale of Hometrack. Under ZPG’s ownership, Hometrack has grown into a leading provider of residential real estate digital valuation and property risk data & analytics in the UK and Netherlands. The transaction marks a natural evolution for ZPG as the group focuses on its distinct businesses, each performing strongly and well positioned for the opportunities ahead: Zoopla, a leading UK property and homeowner data platform; Alto, the UK’s foremost workflow platform for real estate agents; RVU, a leading distribution and home management platform built on iconic UK household brands, including Uswitch and Confused.com; and Tempcover, a market-leading temporary insurance provider. ZPG and its shareholders remain excited about the outlook for each of these businesses. Charlie Bryant, Chief Executive Officer of Hometrack, said: “ZPG and its shareholders have been outstanding partners, their support has been integral to bui
Paysafe Becomes Envision Racing Title Partner to Build the Future of Fan Engagement; Where Motorsport, Gaming and Payments Become One14.8.2026 09:59:00 CEST | Press release
New alliance will turn Formula E fans into participants, connecting race weekends, gaming and rewards through Paysafe's global payments network, with the team entering the new Gen4 era as Paysafe Envision Racing Paysafe (NYSE: PSFE), a leading payments platform, today announced a title partnership with Envision Racing, one of Formula E's most successful and innovative teams, heralding a new era as Paysafe Envision Racing. Together, the two companies will power the future of connected fan experiences, uniting world-class motorsport, gaming and digital payments into the most engaging, rewarding and sustainable fan ecosystem in sport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260814738341/en/ A new era begins in Formula E as Envision Racing becomes Paysafe Envision Racing. The partnership is built on a simple idea: fans shouldn't have to choose between watching the action and being a part of it. From the grid to gaming, es
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom